Form 4: iRhythm Executive Boosts Stake After RSU Vesting

iRhythm Holdings' Chief Medical/Scientific Officer, Minang Turakhia, increased beneficial ownership of common stock following the vesting of performance-based Restricted Stock Units, partially offset by tax-related sales.

Summary

• Minang Turakhia, Chief Medical/Scientific Officer and EVP Advanced Technology at iRhythm Holdings, Inc. (IRTC), reported changes in beneficial ownership of common stock.
• On February 24, 2026, Turakhia acquired 15,060 shares of common stock at a price of $0, resulting from the vesting of performance Restricted Stock Units (RSUs) granted on February 27, 2023, after performance conditions were met.
• Following this acquisition, Turakhia's beneficial ownership stood at 56,703 shares.
• On February 25, 2026, Turakhia disposed of 7,804 shares of common stock at a price of $135.4189 per share.
• These shares were sold to cover tax withholding and remittance obligations associated with the vesting of the performance RSUs.
• After the disposition, Turakhia's beneficial ownership decreased to 48,899 shares.
• A holding company reorganization occurred on January 12, 2026, where iRhythm Holdings, Inc. became the successor issuer to iRhythm Technologies, Inc., with all outstanding shares and equity awards converting on a one-for-one basis without changing proportionate interests.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive. The RSU vesting indicates successful achievement of performance targets, and while there's a tax-related sale, the executive's net beneficial ownership increased, signaling continued commitment.

Positives

• The vesting of 15,060 performance-based Restricted Stock Units indicates that the Compensation & Human Capital Management Committee of the Board determined that performance conditions were met, reflecting positively on company and executive performance.
• Despite tax-related sales, there was a net increase in the reporting person's beneficial ownership of common stock (15,060 acquired vs. 7,804 sold), signaling continued alignment with shareholder interests.

Negatives

• The disposition of 7,804 shares, even for tax purposes, reduces the direct equity stake held by a key executive.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving the vesting of performance-based Restricted Stock Units followed by sales to cover tax obligations, are common occurrences for executives in publicly traded companies. The net increase in beneficial ownership for Minang Turakhia, a key officer, suggests continued confidence in iRhythm's long-term prospects, aligning with typical executive compensation structures in the medical technology sector.

Corporate Governance

Stakeholder Impact

• Shareholders: The net increase in an executive's beneficial ownership, even after tax sales, can be viewed as a positive signal of management's alignment with shareholder interests and confidence in the company's future.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction involving the vesting of performance-based RSUs and subsequent tax-related sales. While the net increase in beneficial ownership is a minor positive, such transactions are generally expected and do not provide a strong signal for a significant change in investment thesis. Therefore, a 'hold' recommendation is appropriate as it does not present new information warranting a 'buy' or 'sell' decision.

Keywords

iRhythm Holdings, IRTC, Form 4, Insider Transaction, Restricted Stock Units, Executive Compensation, Stock Ownership, Corporate Governance